Study on the Effect of Percutaneous Coronary Intervention in the Treatment of Chronic Coronary Syndrome

Objective: To analyze the clinical effect of percutaneous coronary intervention in the treatment of chronic coronary syndrome. Methods: 120 cases of chronic coronary syndrome patients who received inpatient treatment in a hospital from July 2023 to June 2024 were selected as the object, and were divided into the control group and the observation group using the mean score method, each with 60 cases, the control group was treated with conventional medications (aspirin, carbamazepine, β-receptor blockers, angiotensin-converting enzyme inhibitors, statin and other medications), and the observation group was treated with percutaneous The observation group implemented percutaneous coronary intervention based on this treatment, comparing the therapeutic effects of the two groups. Results: The treatment efficiency of the observation group (98.33%) was significantly higher than that of the control group (86.67%), and the difference was statistically significant (P < 0.05); before treatment, the IVPWTd and LVEDd indexes of the patients in the control group and the observation group were (10.39 ± 0.86) mm, (55.36 ± 5.67) mm and (10.41 ± 0.78) mm, (56.01 ± 6.80) mm, respectively. The difference was not statistically significant (P > 0.05); after 3 weeks of treatment, all the indexes of the two groups decreased significantly, respectively (9.76 ± 0.62) mm, (53.28 ± 5.63) mm and (8.56 ± 0.49) mm, (49.65 ± 5.47) mm, and the observation group was significantly lower than the control group, and the difference was statistically significant (P < 0.05). In the control group, 3 cases of arrhythmia and 2 cases of coronary artery spasm occurred during the treatment period, and 1 case each of residual cardiac insufficiency, acute thrombosis, chronic renal impairment, and cardiogenic death, with a total incidence rate of 15%, while in the observation group, only 1 case of arrhythmia and 1 case of coronary artery spasm occurred, with a total incidence rate of 3.33%, and the difference between the groups was statistically significant (P < 0.05). Conclusion: Percutaneous coronary intervention for the treatment of chronic coronary syndrome combined with renal disease is effective, can significantly improve the level of patients’ left ventricular function and reduces the risk of related complications, and is recommended to be popularized and applied in the clinic.